knowledge -WSS

knowledge

author：knowledge 2025-10-01 17:35:27 - browse：267

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： In early work, researchers turn to CRISPR to treat Alzheimer's

entertainment

WSS

Genentech weighs delaying cancer therapy after drug pricing law

Group opposing PBM reform sets lobbying record

Biden tests positive for Covid

Kim Kardashian sparks debate on benefits of full

Medicare to cover more brain scans for Alzheimer’s patients

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

entertainment

knowledge

Wikipedia

Peter Hotez and the public health issue of online harassment

Google and Epic fight stronger regulation of AI in health care

Jerome Adams on the need for new antivirals for Covid

Novo acquires Inversago for up to $1 billion

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Covid's long

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

After John Oliver segment, STAT readers share their opioid

Jerome Adams on the need for new antivirals for Covid

FDA approves RSV monoclonal antibody for infants, toddlers

focus

Group opposing PBM reform sets lobbying record

Kim Kardashian sparks debate on benefits of full

In early work, researchers turn to CRISPR to treat Alzheimer's

Custom gene therapy hints at new path for rare disease treatments

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Medicare to cover more brain scans for Alzheimer’s patients

Wikipedia

entertainment

focus

explore